Enlivex is a clinical-stage macrophage reprogramming immunotherapy company that targets diseased macrophages in patients with sepsis. The company develops an autologous and allogeneic drug pipeline for the treatment of autoimmune and inflammatory conditions such as Graft versus Host Disease (GvHD), solid organ transplant rejection, Crohn's Disease, and other autoimmune and inflammatory disorders. The company's revolutionary approach is to induce immune tolerance by injecting apoptotic cells and facilitating their interaction with dendritic cells activates the body's innate, physiologic mechanism for down-regulating inflammation and autoimmunity. Enlivex is an Israeli-based cell immunotherapy company established in October 2005 by Professor Dror Mevorach, a world-renowned expert on clearance of dying (apoptotic) cells.

Evergreen Therapeutics engages in the research and development of clinical drugs in the field of immunity and ophthalmology.

Defensin Therapeutics ApS

Serpin Pharma is a privately held, development stage biotech company with research facilities in Northern Virginia, USA. We are developing a family of first in class anti-inflammatory and immune modulating peptides with potential application in inflammatory, autoimmune and infectious diseases.

Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA.

Taian Qihang Biotechnology Co., Ltd., established on 2017-04-25, The scope of business includes engaging in biological,medicine,Technology development in the field of science and technology,consult,Serve,Production,Sales(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Signpath Pharma is a development stage biotechnology company founded in 2006. Its lead compound is 99.2% pure synthesized curcumin (diferuloylmethane). Curcumin has an extensive and long history in humans as a mixture of naturally occurring curcuminoids in extracts of the root of the Curcuma longa plant. Traditional use of curcumin has been restricted to topical skin and gastrointestinal conditions because of negligible absorption when given orally. To extend its clinical use Signpath is developing three different intravenous nanoparticle-sized formulations; liposomal, polymeric, and PLGA. Proof of efficacy of these formulations against human tumor xenografts in mice has been established. Following intravenous injection of each formulation, we observed transport across the blood brain barrier in mice, rats, and localization in the hippocampus, brainstem and the striatum.

Atriva Therapeutics is a biopharmaceutical company which aims to develop new antiviral therapies against different respiratory viral infections. Atriva Therapeutics completed preclinical development of ATR-002 and recently filed a request for scientific advice from a European regulatory authority to provide guidance on the executed preclinical development program and the planned ATR-002 Phase I study in healthy volunteers.

Geistlich Pharma AG researches, manufactures and provides pharmaceutical products, gelatine products, biomaterials and industrial glues. It offers Geistlich Bio-Oss and Geistlich Bio-Gide products. The firm specializes in biomaterials for the regeneration of bone, cartilage and tissue and develops, and manufactures medical devices. The company was founded in 1851 and is headquartered in Wolhusen, Switzerland.

Cellivery’s therapeutic drug candidates are being developed for the prevention of life-threatening lethal diseases, including various cancer. The company’s subsequent drug discovery programs will focus on other diseases, in which the transient suppression of either symptoms or etiology would produce long-term benefits, that are both cost-effective and associated with a high quality of life. Cellivery Therapeutics Inc. was founded by Dr. Daewoong Jo, President and CEO in March of 2014. Its earliest notions have been prepared, however, when Dr. Jo began to study for his doctoral thesis at Vanderbilt University, Nashville, TN, USA in 1997.

ETI have developed a patented, unique medical device that removes galectin-3 from human blood. The device removes both bound and free galectin-3 from the circulation, offering a new treatment option that is less invasive and has fewer side-effects than other therapies. The single-use apheresis column selectively removes Galectin-3 from the body. It contains a proprietary, highly effective capturing molecule and is built in a format that hospitals already know how to use.

Novozymes is a world leader in bioinnovation. Novozymes works with its partners to innovate new solutions and rethink industries around the world. Novozymes' industrial enzymes, microorganisms, biopolymers, and other proteins allow its customers to achieve more efficient use of raw materials, reduce energy consumption, replace traditional chemicals with more sustainable alternatives, and offer higher-quality products. Novozymes rethinks everyday products every day.

IncellDx, Inc. detects and monitors life threatening diseases. It offers transformative diagnostic and prognostic clinical patient information based on an innovative technology platform that enables simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers. The company was founded by Bruce K. Patterson and Carol Penfold-Patterson on December 3, 2009 and is headquartered in Menlo Park, CA.

Palatin Technologies is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for treating diseases with significant unmet medical needs and commercial potential. Their programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Their primary product in clinical development is bremelanotide for treating female sexual dysfunction (FSD). In addition, they have drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, and inflammatory diseases. Their current focus is on the design and development of receptor-selective melanocortin agonists for inflammation and autoimmune conditions, with a focus on ocular diseases. Their therapeutics work by activating endogenous melanocortin pathways to resolve damaging inflammation and allow affected tissues time to heal. Research has shown melanocortin agonists can prevent and reverse inflammation in disease models, including in the eyes and intestine—two of their targeted areas.

MimeTech Srl was incorporated in December of 2004 by two scientists, Antonio Guarna, Professor of Organic Chemistry, and Federico Cozzolino, Professor of Clinical Laboratory Sciences, both at the University of Firenze, to further develop pharmaceutical applications of a novel library of synthetic neurotrophin mimetics.

Ashvattha Therapeutics creates products that selectively target and treat human diseases. Ashvattha enables precision targeting for therapeutics eliminating off-target toxicity, systemic side effects, and immunogenicity seen in other platforms. Ashvattha has a pipeline of nine therapeutics in neurology, oncology, and ophthalmology.

Medsenic SAS engages in medical research and develops drugs. It is a biopharmaceutical start-up, which is committed to exploiting new possibilities offered by the therapeutic use of arsenic trioxide, by providing a treatment for autoimmune diseases. The company was founded by Francois Rieger in 2010 and is headquartered in Strasbourg, France.